research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Antibody-drug conjugate induced hair loss responds to minoxidil: A case report
Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Cancer-Related Alopecia Risk and Treatment
Scalp cooling helps prevent hair loss during chemotherapy, and minoxidil aids regrowth.
research Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
RC48 shows promise for treating certain advanced cancers, but more research is needed.
research Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
research Improving Quality of Life During Chemotherapy: Cannabinoids, Cryotherapy, and Scalp Cooling
Cannabis, cryotherapy, and scalp cooling can help improve the quality of life for chemotherapy patients.
research Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
Early detection and multidisciplinary management of skin and mouth side effects from breast cancer treatments improve patient outcomes.
research Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia
Insurance coverage for scalp cooling will make it more accessible to all chemotherapy patients.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss
Chemotherapy for breast cancer often causes significant and lasting hair loss.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
research Tufted hair folliculitis in a woman treated with trastuzumab
Trastuzumab may cause tufted hair folliculitis as a side effect.
research Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
research Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab
Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
research Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
Most patients treated with trastuzumab and paclitaxel experience some hair loss, but it's usually not severe.
research Permanent chemotherapy-induced alopecia: Case report and review of the literature
Some chemotherapy can cause permanent hair loss.
research Multiple drugs
Some breast cancer treatments caused long-term hair loss in women, similar to a condition called alopecia areata.
research Abstract P1-12-19: A case report of successful hair preservation using scalp cooling with doxorubicin and cyclophosphamide during pregnancy
Scalp cooling can effectively prevent hair loss during chemotherapy in pregnancy.
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Cancer vaccine strategies and studies of human thioredoxin reductase splice variants
Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
research Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
Cetuximab can cause unusual hair growth and hair loss.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.